InsidersTradesSigma
Total declarations
Companies
▲ Purchases (85 ops.)
▼ Sales (9 ops.)
Insider track record
Board DirectorDisclosed buys
85
Disclosed sells
9
T+90 hit rate
23%
T+90 mean return
-7.8%
Across 40 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by RA CAPITAL MANAGEMENT, L.P., Board Member. Officer active across 38 companies, notably Werewolf Therapeutics, Inc.. In total, 170 disclosures have been recorded. Breakdown: 85 buys · 9 sells. Total volume traded: €692.2m. History available since 26 May 2021. The latest transaction was disclosed on 3 June 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations170 total
31,000 sharesCommon StockSEC:0001231919-26-000711:0
Ideal exit: 22 Mar 2027 (T+270)
1,876 sharesCommon StockSEC:0001231919-26-000711:1
Ideal exit: 23 Mar 2027 (T+270)
124,893 sharesCommon StockSEC:0001231919-26-000656:2
Ideal exit: 13 Mar 2027 (T+270)
391,019 sharesCommon StockSEC:0001231919-26-000656:0
Ideal exit: 9 Mar 2027 (T+270)
15,414 sharesCommon StockSEC:0001231919-26-000656:1
Ideal exit: 12 Mar 2027 (T+270)
103 sharesCommon StockSEC:0001231919-26-000625:1
Ideal exit: 7 Mar 2027 (T+270)
548,580 sharesCommon StockSEC:0001231919-26-000625:2
Ideal exit: 8 Mar 2027 (T+270)
479,039 sharesCommon StockSEC:0001231919-26-000625:0
Ideal exit: 6 Mar 2027 (T+270)
35,500 shares0Common StockSEC:0001231919-26-000604:0
6,387 shares@ US$24.90100.0% of flowCommon StockSEC:0001231919-26-000495
Ideal exit: 6 Feb 2027 (T+270)
6,387 shares@ US$24.9050.0% of flowCommon StockSEC:0001231919-26-000495:0
Ideal exit: 6 Feb 2027 (T+270)
1,813,439 shares@ US$1.854598.6% of flowClass A Common StockSEC:0000929638-25-001950:0
320,913 shares@ US$0.862.4% of flowCommon StockSEC:0001415889-25-012942:0
Ideal exit: 6 Feb 2026 (T+270)
24,300 shares@ US$1.9851.4% of flowClass A Common StockSEC:0000929638-25-001870:0
1,062,326 sharesCommon StockSEC:0001415889-25-011583:0
1,296,296 shares@ US$13.5043.5% of flowCommon StockSEC:0001415889-25-008257:0
Ideal exit: 8 Dec 2025 (T+270)
304,287 shares@ US$30.5613.7% of flowCommon StockSEC:0001415889-25-007443:0
Ideal exit: 30 Nov 2025 (T+270)
800,189 sharesCommon StockSEC:0000929638-25-000822:0
5,021,990 sharesCommon StockSEC:0001415889-25-003504:0
5,714,285 shares@ US$8.7536.4% of flowCommon StockSEC:0001415889-25-002760:0
Ideal exit: 27 Oct 2025 (T+270)
16,897,159 sharesCommon StockSEC:0001415889-24-030247:0
535,000 shares0Common StockSEC:0001415889-24-028837:0
389,716 shares@ US$14.912100.0% of flowCommon StockSEC:0001415889-24-027924:0
1,220,681 shares@ US$16.2532.3% of flowCommon StockSEC:0001415889-24-026718:0
Ideal exit: 5 Aug 2025 (T+270)
184,331 shares@ US$21.7078.8% of flowCommon SharesSEC:0000929638-24-003752:0
Ideal exit: 1 Aug 2025 (T+270)
25 of 170 declarations
About RA CAPITAL MANAGEMENT, L.P.
RA Capital Management, L.P. is a multi-stage investment manager focused on building and backing healthcare and life science companies. In the context of its publicly traded U.S. portfolio companies, including 89bio, Janux Therapeutics, Acumen Pharmaceuticals, Werewolf Therapeutics, and Therapeutics Acquisition Corp., the most notable role associated with RA Capital is that of long-term investor and board-level governance participant. Public company filings show that RA Capital professionals frequently serve as directors or investor-representatives, with active involvement in strategic oversight, capital allocation, and development planning. RA Capital is widely known for its evidence-based investing approach and for combining scientific analysis with competitive-landscape research through its TechAtlas capability. The firm invests across private and public markets, supports company formation, and works with businesses from discovery through commercialization. That model is reflected in the companies linked to RA Capital, which are typically focused on innovative therapeutic areas such as oncology, neurodegeneration, rare disease, and next-generation biotechnology. Notable public evidence of RA Capital’s activity includes financing support, board participation, and strategic engagement around clinical development and corporate growth. In multiple portfolio companies, RA Capital-linked directors have been part of decisions affecting governance, capital structure, and pipeline prioritization. Rather than a single operating executive role, RA Capital’s significance lies in its consistent board influence and its strategic support of emerging and public biotech companies in the United States market.
